TCGA-XF-A8HC-01A-11R-A36F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6.570302234
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.370
- BILE_ACID_METABOLISM+0.320
- FATTY_ACID_METABOLISM+0.230
- PANCREAS_BETA_CELLS+0.210
- SPERMATOGENESIS+0.210
- CHOLESTEROL_HOMEOSTASIS+0.200
- OXIDATIVE_PHOSPHORYLATION+0.180
- PEROXISOME+0.180
- DNA_REPAIR+0.170
- KRAS_SIGNALING_DN+0.130
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ANGIOGENESIS-0.510
- ALLOGRAFT_REJECTION-0.500
- INFLAMMATORY_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.480
- TGF_BETA_SIGNALING-0.460
- INTERFERON_ALPHA_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- NOTCH_SIGNALING-0.420
- WNT_BETA_CATENIN_SIGNALING-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2615 | Med | Medulloblastoma | 0.890 |
| 2 | TCGA-E9-A54Y-01A-11R-A466-07 | — | B | 0.882 |
| 3 | SRR12202497 | — | — | 0.878 |
| 4 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.876 |
| 5 | TCGA-GV-A40G-01A-11R-A23N-07 | — | — | 0.863 |
| 6 | ERR2278863 | — | — | 0.859 |
| 7 | MDT-AP-2074 | Med | Medulloblastoma | 0.859 |
| 8 | 556f81a3-4af4-4ecb-9b4d-97ecb7cacd56 | — | — | 0.855 |
| 9 | R70 | — | — | 0.855 |
| 10 | MDT-AP-1323 | Med | Medulloblastoma | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |